Tags Posts tagged with "Donald Trump"

Donald Trump

0 754

How Have Marijuana Stocks Performed Post Trump?

Here we are, the official inauguration day of our 45th President of the United States of America, Donald Trump. A lot has been said about him over the last few years during the election race but what many may not have expected was a clear “Trump Bump” for marijuana stocks.

As we’ve said in the past, a lot of marijuana stocks are event driven. Going all the way back to 2014 and during the years to follow, catalysts in the cannabis market can be tied to actual events in many cases. For this most recent jump in marijuana stock prices, we see that an election year and a not so conservative President may be the event to thank for this.

In this article we’ll briefly explore some of the most active and most bullish marijuana stocks in the market to give a clear example of “where we’ve been” and what we might be able to look forward to as to “where we’re going”.

OWC Pharmaceutical Research Corp. (OWCP) 3,512%

This company has been building steam since October and just recently went into overdrive to all time highs. Through its subsidiary, One World Cannabis, the Israeli-based company develops cannabinoid-based therapies that target different medical conditions. This was another cannabis biotech company that saw the impact of Trump coming into office instead of Clinton (who was very bearish on biotech).

In late October just before the elections, OWCP saw its first noticeable move from under $0.03 and initially ran to highs of $0.215. Following the consolidation period heading into the end of the year (as most marijuana stocks saw), January opened the door for this stock to run as high as $0.95

OWCP_Marijuana_Stocks

 

Rocky Mountain High Brands (RMHB)
271%

We’ve reported on this company and followed it for a few years. Even before when it was “Totally Hemp Crazy (THCZ)” this stock saw one of the biggest breakouts that we’ve every witnessed. It went from sub penny to highs of 0.32 within weeks. Now it appears that chart has demonstrated a similar Trump Bump that many of the other marijuana stocks have also seen.

In early October, volume began to build, RMHB ran from $0.031 to highs of $0.07. After consolidating back to 0.03-0.04, RMHB has now seen its 2017 rally trigger and has now managed to run past $0.11. Rocky Mountain is a consumer goods company specializing in brand development of health conscious, hemp-infused food and beverage products. The Company currently markets a lineup of four naturally flavored hemp-infused beverages (Citrus Energy, Black Tea, Mango Energy and Lemonade) and a low-calorie Coconut Lime Energy drink. Rocky Mountain High Brands also offers hemp-infused 2oz. Mango Energy Shots and Mixed Berry Energy Shots, as well as a Relaxation Brownie.

Marijuana Stock

Ubiquitech Software Corp. (UBQU)
304%

UBQU follows a similar trend where even though it hasn’t broken above its year end highs, the stock has seen a reversal that started at the beginning of 2017. A lot of questions were raised regarding a previously announced name change and recently the company gave clear guidance on this for 2017 that has brought attention back to the stock from market bulls. Its final name change will be Endo BioSciences Inc., and HempLife Today™ will continue to be the main subsidiary of the company.

HempLifeToday™ focuses on the exciting and dynamic new thinking in the world today that recognizes the important health and life enriching enhancement that CBD Oil from the Hemp plant can bring. Through its network of quality USA growers HempLifeToday.com™ has developed multiple and proprietary CannazALL™ CBD oil products that include; its popular CBD Tinctures, Oils, GelCaps, CBD Powder, Skin Salve, Wax Crumble, and e-liquid.

marijuana stocks

mCig, Inc. (MCIG)
1,265%

A company that we’ve kept up with for the better part of the last year, MCIG became another clear example of what marijuana stocks have started to look like after Donald Trump was elected President. The company has been making many key strides over the last few months including posting some of its best numbers in history.

This includes MCIG currently holding over $10 million in order/contract backlog (as of their last PR in December). In similar fashion to OWCP, shares of MCIG saw a bump in late October when the stock moved from under $0.04 to as high as $0.218. After consolidating in early December, MCIG manage to rally strong heading into the end of the year and recently hit highs of $0.505.

cannabis stocks

Axim Biotechnologies, Inc. (AXIM)
3,941%

Another company that we’ve been following very closely, this has been one of the biggest runners of the year amid heavy volatility. Another cannabis biotech, the company focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. MJNA is also an investor in AXIM.

In late October the stock was trading just under $0.50 moved to a high of $10 before consolidating to levels between $7.50-$8. Wouldn’t you know it, heading into the beginning of 2017 the stock broke the sideways trend and moved to highs of $19.80.

cannabis stock

Vitality Biopharma (VBIO)
361%

A company that many of us are familiar with, this cannabis biotech had a smaller run a few weeks before we started picking up coverage. In early October, the stock moved up from around $0.92 to highs of $1.84. After pulling back to lows in December, we began looking at this company at $0.98 and watched as it ran to highs of $4.24. The company is a cannabis biotech focusing on treating disease through its prodrug utilizing cannabinoids for the treatment of serious neurological and inflammatory disorders.

marijuana

Cannabis Science (CBIS)
469%

The company specializes in the development of cannabinoid-based medications and recently announced a collaborative research agreement with Dana Farber/Harvard Cancer Center. Their initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

From October 3 to October 19 CBIS jumped from $0.0169 to as high as $0.077. After pulling in during December, the stock kicked off the new year with a big bull run all the way to highs of $0.0961 for the year so far.

cannabis

Hemp Inc. (HEMP)
103%

One of the most vocal companies on Hemp production in the US, Hemp Inc. They’ve continued to push for a ubiquitous acceptance for all uses of the hemp plant for years now and have targeted North Carolina to grow over 3,000 acres of hemp.

“We are proud to collaborate with other American industrial hemp farmers as we now become part of the modern industrial hemp farming movement. This is a turning point for America and it’s a turning point for Hemp, Inc. Hemp, Inc. has the infrastructure in place to process millions of pounds of hemp fibers and stalks a year, on a commercial level. Our 70,000 square foot industrial hemp processing facility, on over 9 acres in Spring Hope, North Carolina, is the only one of this magnitude in North America. The industrial hemp crop is part of history in the making and it is something that will prove to be lucrative not only for the farmers in North Carolina but for Hemp, Inc. as well,” said CEO Bruce Perlowin in a recent PR.

HEMP saw a bump in volume early in October, the stock ran from $0.0276 to $0.056 before consolidating in late November/December, and has once again begun to aggressively climb back from that price channel.

hemp

Cannabis Sativa, Inc. (CBDS)
195%

With multiple subsidiaries, this company has products ranging from hemp oils & capsules to cannabidiol infused bottled water and even its own patented cannabis plan named Ecuadorian Sativa (Patent PP27,475). Back in late September the stock was trading around $2.80 per share before it jumped up to highs of $8.25. After consolidating for weeks leading up to the new year, CBDS has once again followed suit of many marijuana stocks having now climbed back above $8.

CBD

OH CANADA!

This leads us to our “neighbors up north” because we haven’t just seen a boom from US marijuana stocks alone. The trend has echoed into Canada with some of the most anticipated IPOs so far this year

Emblem Corp. (TSXVENTURE:EMC)(OTCQB:EMMBF)
55%

Emblem Corp, a Licensed Cultivator out of Paris Ontario is one of the most watched and anticipated offerings that has come out of Canada in the last few months. Beyond the fact that they are already growing cannabis and revenue producing investors have taken note of one of their founders and current President, a gentleman by the name of John Stewart.

No, not John Stewart from the Daily Show even though that would be awesome, John Stewart former CEO of Purdue Pharma one of the largest private biotech companies in the world and creators of OxyContin. We see the potential long term to create a cultivator/Biotech hybrid in which case Emblem could be the Next GW Pharma of Canada.

Marijuana IPO

InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) (CNSX: IN)
326%

This company has been following the same pattern as many of the other cannabis biotechs but also comes with what looks to be a stock promotion behind it. The company recently appointed Jeff Charpentier, CPA, CA as InMed’s Chief Financial Officer & Corporate Secretary as well as Martin Bott to its Board of Directors; Bott has worked at Eli Lilly & Company since 1988 and held a variety of roles in the U.S., Switzerland, Germany, and the UK.

InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. IMLFF saw a rise in price early in October (shocker right?), a period of consolidation leading up to the new year, and since that ball dropped, the stock has been on the run moving from $0.10 in October to highs of $0.4261 just a few days ago.

Marijuana Stocks

Aurora Cannabis Inc. (TSXV: ACB) (OTCQB: ACBFF)
179%

The company’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) and operates a 55,200 square foot, expandable, state-of-the-art production facility in Mountain View County, Alberta, Canada.

They just announced that the company has officially surpassed 12,000 registered patients within the first 12 months of product sales in Canada. They also announced that they had signed a Joint Venture Research Agreement with Radient Technologies Inc. (“RTI”). The first phase of this venture will include screening experiments of extraction conditions, while phase two includes larger scale experiments related to extraction throughput and optimal extraction conditions. Aurora’s scientists and the RTI team will commence tests January 16, 2017, and the first phase is expected to be completed within approximately six weeks, so something to keep an eye on here in our opinion.

Likewise with the other stocks, the market activity has followed suit even though Aurora has differed by not breaking a new high this year as compared to the high it made in November. But the new uptrend on the chart could be a key indicator for future potential. Since October (at $1.06), shares of ACBFF has seen two and possibly three clear runs; One that saw highs of $1.89 before consolidating, another that saw highs of $2.96 before consolidating, and possibly a new uptrend forming now in January.

Buy marijuana stocks

These are just a few marijuana stocks that have demonstrated a near identical move in the market both leading into the election and leading up to the inauguration. We’ve said it before and most likely will say it again: Marijuana Stocks can very much be event driven so something to keep in the back of your head as we watch 2017 unfold. As investors become more informed on the industry itself, we’ll keep our had on the pulse to find the real story behind some of the biggest marijuana stock moves in the market today.

 

 

 

 

 


 

Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Pursuant to an agreement between MAPH and Ubiquitech Software Corp., we were hired for a period beginning November 11 2016 and ending May 11, 2017 to publicly disseminate information about (UBQU) including on the Website and other media including Facebook and Twitter. We are being paid $0 (CASH) for or were paid “10 million” shares of restricted common shares. MAPH owns 2 million common restricted shares of mCig Inc. MAPH owns 10 million common restricted shares of Hemp Inc. An affiliate of MAPH owns 70,850 common restricted shares of Emblem Corp. We may buy or sell additional shares of any stocks mentioned, in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information

1 2143

If the American people are concerned with Republican Senator Jeff Sessions’ approach to implementing federal cannabis laws, he says Congress should adjust them. Sessions, who President-elect Donald Trump has chosen to become U.S. attorney general, answered questions on cannabis among other issues during his confirmation hearing on Tuesday. Sessions did not offer a clear stance on what cannabis enforcement would look like under his justice department. Sessions stated, “I won’t commit to never enforcing federal law, but absolutely it’s a problem of resources for the federal government. Good judgement on how to handle these cases will be a responsibility of mine, which won’t be an easy decision, but I will try to do my duty in a fair and just way.”

Even though 28 states have made medical cannabis legal and eight states have passed recreational laws, the federal law still classifies marijuana as an illegal substance. The drug is classified as a Schedule I drug along with heroin. In the past, Sessions has made it clear he is against the legalization of marijuana. He said, “Good people don’t smoke marijuana.” However, in a Trump presidency, he would be asked to follow the Trump agenda and not his own. This gives the cannabis industry hope.

Almost 60% of Americans support the legalization of cannabis in the United States. The seven states that voted to legalize medical or recreational use are looking to take steps toward legalization. “It’s not so much the attorney general’s job to decide what laws to enforce. We should do our jobs and enforce laws effectively as we’re able. The U.S. Congress made the possession of marijuana in every state, and the distribution, an illegal act. If that’s something that’s not desired any longer, Congress should pass a law to change the rule,” Sessions said during his hearing.

1 5981

The Farm, a pot shop in Boulder, Colorado is staffed with cannabis advocates, known as “bud-tenders.” The shop is booming, to the benefit of all Boulder’s residents. The city’s sales tax on recreational marijuana is almost 23% and high demand for warehouse space from cannabis farmers points to a boom. Colorado is expected to have collected almost $135 million from marijuana taxes last year. Following its example, recreational marijuana will be legal in seven states and Washington, DC. Another 24 states allow cannabis to be used for medicinal purposes.

Because marijuana is still illegal under federal law, any pot shop is, in effect, a US attorney-general’s impulse away from closure. Senator Jeff Sessions, whom Trump has nominated to be attorney-general, has a different view. He said, “We need grown-ups in Washington to say marijuana is not the kind of thing that ought to be legalized.” He also stated, “good people don’t smoke marijuana.” Trump has taken conflicting positions on the issue. When Trump was campaigning, he said whether marijuana should be legal was a matter for individual states to decide. But he also called Colorado’s cannabis regime “a real problem.” Vice-president-elect Mike Pence has presided over one of America’s toughest anti-cannabis administrations.

Marijuana advocates are worried. Andrew Freedman, Colorado’s director of marijuana a coordination said, “There’s very good reason to be concerned. This could become an enforcement priority.” A spokesman for The Farm, Adam Dickey, agreed. “It’s a little scary, we are very concerned, though we’re not in full-on panic mode yet,” Dickey stated. It’s difficult to envision Senator Sessions carrying out the clampdown he wants. Almost 60% of Americans say they are in favor of legalizing pot. That represents a swelling consensus in favor of legalization. There is no reason to expect that increasingly casual attitude to go into reverse. Legalizing marijuana looks largely successful.

0 3367

On Election Day, residents of California made their vote to become the world’s biggest legal marijuana market, along with seven more states who also voted yes on recreational or medical pot. Originally, President-elect Donald Trump’s shocking victory didn’t seem to pose an immediate threat to the legal pot industry; Trump isn’t popular in the cannabis world, but he’s not seen as a committed prohibitionist either.

At a post-election industry conference in Vegas, the largest controversy involved a nearly naked model covered in cold cuts. That outlook changed after Trump picked Sen. Jeff Sessions, an Alabama Republican, as his nominee for attorney general. While many conservatives have relaxed their outlook on both marijuana and criminal penalties for drug offenses, Sessions evidently has not.

“We need grown-ups in charge in Washington saying marijuana is not the kind of thing that ought to be legalized,” he said at a hearing in April.

“It is, in fact, a very real danger.” To liberals, the Sessions nomination is, as the New York Times editorialized, “An insult to justice.” Sessions had been rejected for a federal judgeship in 1986 due to concerns that he’s a racist.

His nomination in 2016 to the far more powerful position of attorney general raised an immediate outcry from, among others, those concerned with the treatment of undocumented immigrants, the rights of LGBTQ and Muslim Americans, and supporters of criminal justice reform and police accountability. The legal marijuana industry, which is anticipated to top $6 billion in sales this year, also has reason to fear Sessions, but its response has been much more muted.

The National Cannabis Industry Association, the industry’s largest lobby, released a statement saying that it looked forward to working with Attorney General Sessions. They think it’s safer to weather his tenure at the Justice Department than to fight it.

0 1717

Avid Donald Trump supporter, Governor Paul LePage, tried to convince Maine voters that legalizing recreational marijuana would be a “deadly” disaster for the state, to no avail. The Governor of Maine is now trying to do away with medicinal cannabis.

On Election Day voters barely approved question 1, which legalizes two and a half ounces of cannabis and six mature plants for adults 21 and over. Since the margin of victory was so close, the opponents requested a recount. Now delayed because of a lack of volunteers from the opposing side to help count, the results will have to wait until 2017.

While awaiting results LePage is trying to convince the state legislature to do away with medicinal marijuana. “Why do we need medical marijuana? I see no need,” he stated during an interview on Thursday with news radio station WGAN. “You don’t need a prescription to buy a Bayer aspirin. Why do you need a prescription to buy medical or recreational marijuana?”

Governor LePage appeared in a t.v. ad in which he falsely stated that the legalization of marijuana has led to many traffic deaths in other states and that “people addicted to marijuana are three times as likely to become addicted to heroin.”

When Maine voters didn’t fall for it, LePage threatened that he’d be “talking” to President-elect Donald Trump about the state’s cannabis concern. Trump has selected Alabama Senator Jeff Sessions to run the Justice Department. Sessions once stated that “good people don’t smoke marijuana.”

If that doesn’t help undo things, Governor LePage will see if he can get the state legislature to debilitate the will of the voters and do away with medical cannabis he stated during his radio interview.

“If there ever were a bill that the legislature should just kibosh, that’s it,” he stated. To make matters worse LePage would also like higher taxes on marijuana sales if they decide to keep it around.

0 4505

Despite favorable state-wide election results, concerns among cannabis investors have increased and cannabis stocks continue to move lower following an overextended industry wide rally as well as highly questionable cabinet nominations by president elect Donald Trump.

Although the recent downward trend is concerning, this weakness has created an opportunity for investors to purchase high quality cannabis investments at a considerable discount.

Today, we want to take the time to highlight three recent trends and price movements that investors should be aware of.

Kush Bottles Falls Almost 20% from Last Week’s High

Kush Bottles (KSHB) has fallen more than 18% from its highs on Tuesday and the shares are now trading below the $3 price target issued by Cowen and Company in mid-September. The analyst assigned the shares a Buy rating and a $3 price target because of its unique exposure to the high growth, emerging cannabis industry.

This correction has created a great opportunity for investors as consider Kush Bottles to be one of the best cannabis investment opportunities. We are favorable on Kush Bottles due to the product it provides, its geographic diversity, its growth potential following positive state-wide election results and its continued execution.

The company offers several child resistant and non-child resistant exit bag solutions, all of which are fully customizable, allowing Kush Bottles’ customers the opportunity to creatively market and brand themselves. We find this aspect of its offering to be extremely important as companies compete to become a recognized brand amongst consumers.

Zynerba Fall More than 12% from Friday’s Highs

Zynerba Pharmaceuticals (ZYNE) fell approximately 3% yesterday and we are monitoring ZYNE closely as the shares are down almost 12% from its highs on Friday. This move lower has caused momentum to plunge and we remain favorable on ZYNE at current levels.

Investors should take note of Zynerba’s recent correction since it has followed a more than 15% rally so far this month. We consider Zynerba to be one of the top biotech cannabis investment opportunities due to:

1) its product pipeline, which will create catalysts for the shares over the next few years, 2) its attractive size (from a market cap standpoint) as it is a takeout candidate for a larger pharmaceutical company looking to enter the cannabis sector, and 3) its attractive valuation as the shares come down from recent highs.

Canadian Licensed Medical Cannabis Producers Bounce Back

Although yesterday’s trading activity within the cannabis sector was mixed, certain sub-sectors performed better than other and we are monitoring this activity closely. Canadian licensed medical cannabis producers saw strength yesterday and each member of the Big Five (Canopy Growth, OrganiGram, Aphria, Aurora, and Mettrum) ended the day in positive territory.

Yesterday, Emblem Corp (EMC.V) lived up to the hype during its initial public offering as trading activity exceeded our already high expectations. Emblem is a licensed medical cannabis producer in Canada uniquely positioned within the rapidly growing medical and recreational cannabis industry.

We are favorable on Emblem for the following reasons: 1) The company operates three distinct divisions which can create value for each other, 2) Its initial public offering saw remarkably high interest from the marketplace, 3) Its Emblem Cannabis division started selling medical cannabis in August and we expect to see continued growth on a month-over-month basis, and 4) It is led by a management team that has a proven track record of building successful multi-billion dollar companies.

Important Investor Disclosures

Disclosure. Compensated Affiliate. This report was authored by and is property of StoneBridge Partners LLC. All information and data relied upon in drafting this report is publicly available. The author believes and considers its sources to be reliable, but does not guarantee the accuracy or completeness of any information contained in this report. Any and all information, data, analyses and opinions are provided for informational purposes only and is not intended, in any manner, as investment advice. Any projections or other information generated by StoneBridge Partners LLC regarding the likelihood of various investment outcomes are hypothetical in nature, do not reflect actual investment results, and are not guarantees of future results. None of the material contained in this report is intended as a solution or offer to sell or purchase a specific stock or any other investment. This report is not directed to, or intended for distribution or use by, any person or entity that is a citizen, resident or located in any municipality, state, country or other jurisdiction where the distribution, publication, availability, or use of this report is contrary to any governing law or regulation. The securities discussed in this report may not be eligible for purchase and/or sale in certain jurisdictions or by particular individuals. It is important that you check any and all governing laws and/or regulations that may be applicable in your jurisdiction. Investing in securities of issuers organized outside of the United States, including ADRs, entail certain risks. The securities of non-United States issuers may not be registered with, nor be subject to the reporting requirements of the United States Securities and Exchange Commission. Please contact a Financial Advisor for professional advice regarding any and all securities investments. This report is intended for informational purposes only. StoneBridge Partners LLC’s officers, directors, employees, affiliates, or subsidiaries may have positions in securities covered by StoneBridge Partners LLC. StoneBridge Partners LLC receives compensation from the company and/or has a position in the securities mentioned in this report

Authored By: Michael Berger

7 5596

The biotech sector may be one of the biggest beneficiaries of the legal cannabis movement.

In previous articles, we have been quite vocal about our bullish stance on the cannabis biotech sector. In the current US markets, we believe the greatest opportunity lies in biotech and the pharmaceutical production of cannabinoid and cannabis related drug treatments. And recent political shifts may have just created a perfect storm for cannabis biotech investors. Right now could be your greatest opportunity to consider adding cannabis biotech to your portfolio. And we aren’t the only ones who think so.

Todd Hagopian, manager of a biotech fund at Marketocracy, believes the biotech sector will benefit most from a Donald Trump Presidency. Todd is one of the most successful biotech investors in the market today. His returns have averaged 26.03% since starting his fund in 2011, which compares nicely to the S&P 500’s 11.58% return over the same period. Over the last five and three year periods, Todd Hagopian did better than the top U.S. Equity fund managers.

But why are we so bullish on cannabis biotech?

For over a year, analysts have been anticipating and factoring in a Hillary Clinton victory that sent the ishares NASDAQ Biotechnology ETF (IBB) plummeting 23% from 9/21/15 through Election Day this November. Why? Clinton was very vocal about her desire to slash what she believed to be excessive profits in the biotech industry. This would force drug companies to lower prices that would tighten margins and decrease net profit. If Clinton won the election, there were concerns that she would flip the Senate and/or House of Representatives to Democratic control. This would have allowed her to take action on the pricing practices of the biotech sector.

But with the White House and Congress now in Republican control, the biotech sector is set up for an extraordinary comeback. In fact, it has already begun. The IBB is up about 10% since Election Day. With Trump taking the White House, biotech investors could be in for one heck of a ride as this could be just the beginning of a move that could see the biotech sector double.

In an interview with Ken Kam of Forbes, Todd Hagopian said, “After underperforming the S&P 500 by over 30% in the past 14 months, there is plenty of room for this sector to run. In fact, the S&P 500 Biotechs are trading at a Forward P/E of just 22.4% vs. Consumer Staples who are trading at a Forward P/E of 17.2%.  This is pretty remarkable, considering that the same group of Biotech companies have a short term earnings growth rate of 17.3%, versus the Consumer Staple companies who are projected to grow at just 8.0%. Basically, this data would seem to suggest that either there is a huge bubble in Consumer Staples stocks, or the Biotechnology market is about to double.”

This is the perfect storm for cannabis biotech investors. Not only is the overall biotech industry expected to experience a massive bull run, but cannabis legalization is quickly spreading across the US. The November Election Day was an enormous victory for the cannabis industry. There are now 8 states that allow the recreational use of marijuana and another 21 that allow its medical use. We could be looking at a golden opportunity for cannabis biotech investors.

In his interview with Forbes, Hagopian went on to name a few other catalysts that biotech investors seem to have in their favor:

  1. The Obamacare fight needs to stay away from pricing. The odds of a Republican House and Senate trying to pass a law regulating drug prices, and have it signed by a Republican President seems slim to none.
  2. The Supreme Court needs to stay conservative. Donald Trump has already promised to nominate conservative judges to the court. The Supreme Court will likely stay 5-4, or even 6-3, in favor of conservative views.
  3. M&A activity needs to restart. The low valuations seen in the biotech sector after the Clinton selloff mentioned earlier in this article has sparked a ton of M&A rumors in the biotech sector. The Clinton biotech scare not only provided great opportunity for individual investors but also for large biotech titans to swallow up smaller companies with promising intellectual property and clinical data from early drug trials. We have already seen recent M&A activity in the cannabis sector with Canopy Growth Corp., Canada’s largest marijuana company, agreeing to buy competitor Mettrum Health Corp. for $8.42 a share.

The current environments of the overall biotech sector and marijuana industry have created an exciting time for cannabis biotech investors. Several catalysts are aligning for what could be a booming 2017 for the entire space. In addition, many companies are expected to announce FDA clinical and pre-clinical trial data soon. Favorable results will be a catalyst to send individual stocks and the overall cannabis biotech sector considerably higher.

If you haven’t done so already, it’s time to consider adding cannabis biotech to your portfolio, Now!

0 1727

Protection for medical cannabis states may continue through the beginning of 2017 due to federal lawmakers passing a short-term spending bill. Extending the funding bill, which keeps the government operating, (currently expires Dec. 9) may also extend Section 542 (a rider to the funding bill) of the Consolidated Appropriations Act of 2016. This act states that funds may not be used to stop legal medical cannabis states from implementing their laws, Marijuana.com reported:

In August, a federal court ruled — over Justice Department objections — that the provision doesn’t merely block the U.S. government from stopping states from passing their own medical marijuana laws but also prevents federal prosecutors from going after patients and providers who are operating in accordance with those local policies.

But the three-judge panel of the U.S. Court of Appeals for the Ninth Circuit made it clear that the protections provide only temporary relief. Advocates began 2016 feeling confident they’d be able to enact the amendment again. After all, huge bipartisan majorities of the House of Representatives are on record in support. In 2014 the measure passed 219-189. Last year the margin of victory grew to 242-186.

And this year the Senate Appropriations Committee approved the amendment by a vote of 21-8.

Speaker Paul Ryan stated last week that the House would follow a request from President-elect Donald Trump to push a stopgap bill that would enable the government to continue running at the same pace through March, as per The New York Times. Senate Republicans were not necessarily aware of those plans at the time. The Times reported, quoting Sen. Mitch McConnell, R-Ky., as saying, “Discussions are also ongoing about how to fund the government and for how long.”

According to Reuters, (who reported that some Democrats and Republicans do not agree with the short-term funding move) Donald Trump’s administration would like to have a “say-so on how spending is allocated” once he is in office, Ryan said. A senior member of the appropriations committee, Rep. Tom Cole, R-Okla., told The Hill that there may be additions to the short-term bill:

Several members have called for more defense spending as well as additional relief for flood victims. House Appropriations Chairman Hal Rogers (R-Ky.) said Thursday he would personally push to complete the president’s request for supplemental war spending, which the chairman called “terribly important.”

Budget Committee Chairman Tom Price (R-Ga.) and others said pushing this year’s appropriations process into next March will make it tougher to write next year’s spending bills. It will shorten the timeline for the appropriations process, which makes it even tougher as GOP leaders pursue a complex budget tactic called reconciliation.

It is not clear what, if anything, the new administration will do toward existing medical cannabis or recreational cannabis laws in U.S. states. Donald Trump has said he stands behind states’ rights and would not get in the way of legal cannabis states, including recreational states such as Colorado. Alabama Sen. Jeff Sessions is his nomination for attorney general. Sessions is a supporter of states’ rights, but against cannabis legalization and use.

0 1258

With several more states expected to legalize marijuana President Obama believes the federal government will be forced to get serious about changing its laws against the herb.In a recent interview with HBO’s Real Time with Bill Maher, the president explained what was at stake if the voters in five states-Arizona, California, Maine,Massachusetts and Nevada-decide to approve ballot measures intended to legalize marijuana in a manner similar to what is currently underway in four other states and the District of Columbia.

“The good news is is that after this referenda, to some degree it’s gonna call the question, because if in fact it’s passed in all these states, you now have about a fifth of the country that’s operating under one set of laws, and four-fifths in another,” Obama stated.

Obama then went on to tell Maher that the outcome of the upcoming election could cause mass confusion within the federal agencies responsible for enforcing the nation’s drug laws. While those agencies will undoubtedly continue to try and stop interstate drug trafficking, there will likely soon be parts of the United States where even this level of policing no longer makes sense.

“The Justice Department, DEA, FBI, for them to try to straddle and figure out how they’re supposed to enforce laws in some places and not in others they’re gonna guard against transporting these drugs across state lines, but you’ve got the entire Pacific corridor where this is legal that is not gonna be tenable,” he said.

Although President Obama does not believe legalization will remedy all of the issues associated with marijuana, he does think the time has come for the nation to reconsider its position against the plant.

“I don’t think that legalization is a panacea,” Obama said, “But I think that we’re going to have to have a more serious conversation about how we are treating marijuana and our drug laws generally.” Indeed, the time has come for the federal government to starting working toward some concrete reform with respect to the national marijuana laws.

 

0 2330

We as a nation, have come a long way especially when all of the major presidential nominees support state-level medical marijuana programs. There are many concerns on how to judge these candidates, and many perspectives on current events and policies—though, if cannabis-law reform were the single deciding factor, which way would you cast your vote?

Hillary Clinton

The former secretary of state and Democratic candidate running for president is fair on the issue, proposing her qualified support for medical marijuana, although she still believes that more investigative studies ar needed. She also thinks that marijuana should be changed to Schedule II narcotic under the federal Controlled Substances Act, the same category as cocaine, methamphetamine, and OxyContin. Clinton has shown support for the right of states to push forward with marijuana-law reform, even though she stops short of backing legalization at the federal level.

Donald Trump

The Republican nominee is without a doubt the worst of the four running candidates on this concern. Trump has been all over the nation regarding America’s drug laws. In the 1990s, he opined that all drugs should be legalized, but as the GOP candidate, he stands against the legalization of cannabis for adult recreational use. Still, Trump has displayed his support for the right of states to set medical marijuana policies.

Gary Johnson

The former two-term governor of New Mexico is the Libertarian Party candidate and a promising advocate for cannabis law reform. He openly supports the movement towards the legalization of marijuana for medical and recreational purposes, even citing his own use in both areas to make the point. Johnson was once the CEO of a medical marijuana corporation prior to him resigning to run for president.

Jill Stein

The Green Party candidate is also very much admired for her position on marijuana-law reform. Jill Stein was in the medical field for over 2 decades, Stein supports the legalization of marijuana for medical and recreational use and has stated that she would change its Schedule I classification under the Controlled Substances Act, which places marijuana in the same highly restricted category as heroin and OxyContin.

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements